RPL33A Antibody

What is RPL33A and what cellular functions does it perform?

RPL33A (also known as eL33 in the revised nomenclature) is an essential component of the large 60S ribosomal subunit. It plays critical roles in:

• Ribosome biogenesis, particularly in the maturation of pre-ribosomal rRNAs

• Efficient processing of 35S and 27S pre-rRNA precursors

• Production of mature 5.8S and 25S rRNAs

• Maintenance of translation initiation fidelity, particularly in AUG start codon recognition

In yeast, RPL33A is encoded by paralogous genes RPL33A and RPL33B, with RPL33A producing approximately sixfold higher mRNA levels. The human ortholog is known as RPL35A, and mutations in this gene have been associated with Diamond-Blackfan anemia (DBA) .

What are the recommended applications for RPL33A antibodies in research?

Based on available antibody characterization data, RPL33A antibodies are successfully employed in:

• Western blot (WB) analysis with recommended dilutions of 1:2000-1:5000

• Immunohistochemistry (IHC) for tissue localization studies

• Co-immunoprecipitation to study protein-protein interactions

• Immunofluorescence for subcellular localization

For optimal results in Western blot applications, researchers should use 10μg of stromal protein samples denatured at 95°C for 10 minutes and separated on 4-20% SDS-PAGE gels .

What is the molecular weight and expected banding pattern for RPL33A in Western blotting?

• Expected band: 7.6 kDa

• Apparent band: ~10 kDa

The disparity between expected and observed molecular weights is consistent with other ribosomal proteins and should be accounted for when interpreting results .

How should sample preparation be optimized for RPL33A detection in plant tissues?

For optimal detection of RPL33A in plant tissues, the following protocol is recommended:

• Sample collection and storage:

  • Collect fresh plant material (preferably young tissues with active protein synthesis)

  • Flash-freeze in liquid nitrogen and store at -80°C until processing

• Protein extraction:

  • Grind tissue to fine powder in liquid nitrogen using mortar and pestle

  • Extract stromal proteins using buffer containing 50mM HEPES-KOH (pH 7.5), 330mM sorbitol, 5mM MgCl₂, and protease inhibitor cocktail

  • Clarify extract by centrifugation at 16,000g for 10 minutes at 4°C

• Sample preparation for SDS-PAGE:

  • Denature samples at 95°C for 10 minutes in standard Laemmli buffer

  • Load 10-15μg of stromal protein per lane on 4-20% gradient gels for optimal resolution

• Western blot conditions:

  • Transfer proteins to PVDF membrane (0.2μm pore size recommended)

  • Block with 5% non-fat dry milk in TBST buffer

  • Incubate with anti-RPL33A antibody at 1:2000-1:5000 dilution

This methodology has been validated for detection of RPL33A in Arabidopsis thaliana, Hordeum vulgare, and Zea mays samples .

What controls should be included when performing functional studies of RPL33A?

Robust functional studies of RPL33A require appropriate controls to validate results and account for potential confounding factors:

• Positive controls:

  • Wild-type samples expressing normal levels of RPL33A

  • Recombinant RPL33A protein (such as ABIN1666573) for antibody validation

  • Samples from species with confirmed reactivity (Arabidopsis thaliana, Zea mays)

• Negative controls:

  • Cyanobacteria samples (confirmed non-reactive species)

  • Samples treated with RPL33A-specific siRNA (for knockdown verification)

  • Immunoprecipitation with non-specific IgG

• Experimental controls:

  • Parallel analysis of other ribosomal proteins (e.g., RPL3) to distinguish RPL33A-specific effects from general ribosomal defects

  • Complementation with wild-type RPL33A to rescue mutant phenotypes

  • Temperature-sensitive mutants to study conditional phenotypes

Including these controls enables more confident interpretation of results and helps distinguish RPL33A-specific functions from general ribosomal effects.

How can researchers differentiate between RPL33A and RPL33B in experimental systems?

Distinguishing between the paralogous RPL33A and RPL33B proteins presents technical challenges due to their high sequence similarity. Recommended approaches include:

• Genetic approaches:

  • Use of single gene knockout strains (rpl33aΔ or rpl33bΔ)

  • Complementation studies with tagged versions of each paralog

  • Promoter-reporter fusion analysis to monitor differential expression patterns

• Expression analysis:

  • Quantitative RT-PCR with paralog-specific primers targeting unique 5' or 3' UTR sequences

  • Northern blot analysis with probes designed to discriminate between transcripts (resulting in ~6-fold higher signal for RPL33A)

• Protein detection:

  • Mass spectrometry to identify paralog-specific peptides

  • Paralog-specific antibodies raised against unique epitopes

• Functional differentiation:

  • Growth phenotype analysis (only rpl33aΔ shows severe slow growth)

  • Pre-rRNA processing defect characterization (more pronounced in rpl33aΔ)

The differential expression pattern (RPL33A producing ~6-fold more mRNA than RPL33B) provides a natural means of distinguishing their relative contributions to ribosomal function and cellular physiology .

How can mutational analysis of RPL33A be used to study its role in translation initiation fidelity?

Mutational analysis has revealed that RPL33A plays an important role in translation initiation fidelity, particularly in start codon recognition. To investigate this function:

• Generation of RPL33A mutants:

  • Create point mutations at conserved residues (e.g., G76R)

  • Target residues involved in rRNA interactions

  • Develop temperature-sensitive mutants for conditional analysis

• Translation fidelity assays:

  • Measure UUG/AUG initiation ratio using dual luciferase reporters

  • Analyze GCN4 derepression (Gcd⁻ phenotype) as an indicator of translation initiation defects

  • Assess polysome profiles to examine subunit joining and translation elongation

• Molecular mechanism investigations:

  • Test for genetic interactions with translation initiation factors (particularly eIF1)

  • Analyze 60S/40S subunit ratios in mutant strains

  • Examine tRNA binding in P-site and A-site positions

Studies have demonstrated that certain rpl33a mutations increase the UUG/AUG translation initiation ratio (Sui⁻ phenotype), which can be suppressed by eIF1 overexpression. This suggests that RPL33A and proper 60S/40S subunit ratio are critical for accurate start codon recognition .

What approaches can be used to study the role of RPL33A in pre-rRNA processing?

Investigating RPL33A's role in pre-rRNA processing requires multifaceted approaches:

• Pre-rRNA intermediate analysis:

  • Northern blot analysis using probes specific for pre-rRNA spacer regions

  • Pulse-chase experiments with ³H-uridine or ³²P labeling to track pre-rRNA processing kinetics

  • Primer extension analysis to identify precise 5' ends of pre-rRNA species

• Quantitative assessments:

  • Measure 27SA2:27SB pre-rRNA ratios in wild-type versus mutant strains

  • Analyze levels of mature 25S, 18S, and 5.8S rRNAs

  • Determine 60S:40S subunit ratios using sucrose gradient analysis

• Structural studies:

  • Cryo-EM analysis of pre-60S particles in RPL33A-deficient cells

  • Crosslinking and analysis of cDNA (CRAC) to map RPL33A-RNA interactions

  • Molecular dynamics simulations to predict structural perturbations

Research has shown that depletion of RPL33A leads to elevated 27SA2 to 27SB pre-rRNA ratios and reduced levels of 5.8S rRNA with the major 5' end at site B1S, indicating that RPL33A is required for efficient progression from 27SA2 to 27SB pre-rRNA and proper 5.8S rRNA maturation .

What is the relationship between RPL33A mutations and Diamond-Blackfan anemia?

RPL35A, the human ortholog of yeast RPL33A, has been implicated in Diamond-Blackfan anemia (DBA), a congenital bone marrow failure syndrome:

• Genetic evidence:

  • Deletions in chromosome 3q containing RPL35A identified in DBA patients

  • Sequence analysis confirmed RPL35A mutations in DBA cohorts

  • Haploinsufficiency of RPL35A contributes to the DBA phenotype

• Molecular mechanisms:

  • RPL35A deficiency disrupts maturation of 28S and 5.8S rRNAs

  • Impaired 60S subunit biogenesis leads to cellular proliferation defects

  • Pre-rRNA processing alterations are similar between RPL35A-mutated and some RPL35A wild-type DBA patients

• Experimental models:

  • Yeast lacking RPL33A serve as models for studying DBA molecular pathology

  • shRNA inhibition of RPL35A in human cell lines recapitulates DBA cellular phenotypes

  • Patient-derived lymphoblastoid cell lines show characteristic pre-rRNA processing defects

The relationship between RPL35A/RPL33A and DBA demonstrates that alterations in large ribosomal subunit proteins can cause bone marrow failure syndromes and potentially contribute to cancer predisposition .

How should researchers interpret and resolve discrepancies in RPL33A detection across different experimental systems?

When encountering inconsistencies in RPL33A detection across experimental systems, consider these systematic troubleshooting approaches:

• Species-specific considerations:

  • Confirm antibody reactivity with your specific species (see reactivity charts in product documentation)

  • Note that RPL33A antibodies are confirmed to react with Arabidopsis thaliana, Hordeum vulgare, and Zea mays, but not with cyanobacteria

  • Consider using the human ortholog (RPL35A) antibodies for mammalian systems

• Technical variables:

  • Extraction method: Stromal proteins require specific extraction buffers

  • Denaturation conditions: Complete denaturation at 95°C for 10 minutes is recommended

  • Gel composition: 4-20% gradient gels provide optimal resolution

  • Transfer efficiency: Verify with reversible staining methods before immunoblotting

• Biological variables:

  • Expression levels vary by tissue and developmental stage

  • Stress conditions can alter ribosomal protein expression

  • Cell cycle phase may influence detection

• Antibody-specific factors:

  • Epitope accessibility may differ between native and denatured protein

  • Cross-reactivity with related ribosomal proteins should be evaluated

  • Batch-to-batch variation in antibody preparations can occur

When interpreting conflicting results, systematically evaluate these variables and consider using multiple detection methods or alternative antibodies targeting different epitopes of RPL33A .

What are the best practices for validating RPL33A antibody specificity in new experimental systems?

When introducing RPL33A antibodies to new experimental systems, comprehensive validation is essential:

• Positive and negative controls:

  • Include samples from species with confirmed reactivity (Arabidopsis thaliana, Zea mays)

  • Test samples from non-reactive species (cyanobacteria)

  • Use recombinant RPL33A protein as a positive control (e.g., His-tagged RPL33A)

• Knockdown/knockout validation:

  • Perform siRNA/shRNA knockdown of RPL33A

  • Use CRISPR/Cas9 genome editing to generate knockout controls

  • Validate decreased signal correlates with reduced RPL33A expression

• Multiple detection methods:

  • Compare results across Western blot, immunofluorescence, and immunoprecipitation

  • Utilize mass spectrometry to confirm antibody-captured proteins

  • Perform epitope mapping to confirm binding specificity

• Cross-reactivity assessment:

  • Test against closely related ribosomal proteins

  • Perform peptide competition assays with immunizing peptide

  • Evaluate reactivity in multiple tissue/cell types

• Independent antibody validation:

  • Compare results using antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data

  • Confirm colocalization with known ribosomal markers

Following these validation steps ensures reliable results and facilitates accurate interpretation of RPL33A-related findings in new experimental contexts.

How can researchers distinguish between direct effects of RPL33A deficiency and secondary consequences of general ribosomal stress?

Differentiating direct RPL33A-specific effects from general ribosomal stress requires careful experimental design:

• Comparative ribosomal protein analysis:

  • Parallel analysis of multiple ribosomal protein deficiencies

  • Compare phenotypes of RPL33A-deficient cells with those lacking other large subunit proteins

  • Examine whether phenotypes are rescued by wild-type RPL33A expression

• Temporal analysis:

  • Use time-course experiments to identify primary versus secondary effects

  • Employ inducible systems for controlled RPL33A depletion

  • Monitor sequential appearance of cellular phenotypes

• Pathway-specific readouts:

  • Measure p53 activation as an indicator of general ribosomal stress

  • Assess nucleolar stress responses

  • Examine specific pre-rRNA processing steps affected by RPL33A deficiency

• Domain-specific mutations:

  • Generate mutations that disrupt specific RPL33A functions

  • Target residues involved in defined molecular interactions

  • Compare phenotypes of different point mutations affecting distinct functional domains

• Genetic interaction studies:

  • Perform suppressor screens to identify genes that rescue specific RPL33A-deficient phenotypes

  • Test genetic interactions with components of pre-rRNA processing machinery

  • Examine synthetic interactions with translation initiation factors

Research has shown that some rpl33a mutants exhibit specific defects in translation initiation fidelity (increased UUG/AUG ratio) that can be suppressed by eIF1 overexpression, suggesting these are direct effects rather than consequences of general ribosomal insufficiency .

What emerging techniques could advance our understanding of RPL33A's role in ribosome assembly and function?

Cutting-edge methodologies that could further elucidate RPL33A functions include:

• Cryo-electron microscopy (cryo-EM):

  • High-resolution structural analysis of ribosomes with wild-type or mutant RPL33A

  • Visualization of pre-ribosomal particles at different maturation stages

  • Time-resolved structural studies of ribosome assembly intermediates

• Ribosome profiling:

  • Genome-wide analysis of translation in RPL33A-deficient cells

  • Identification of transcripts particularly sensitive to RPL33A deficiency

  • Assessment of translation elongation rates and ribosome pausing

• Proximity labeling techniques:

  • BioID or APEX2 fusions to RPL33A to identify proximal interacting partners

  • Time-resolved interactome analysis during ribosome assembly

  • Spatial mapping of RPL33A interactions in different cellular compartments

• Single-molecule techniques:

  • Single-molecule FRET to study RPL33A's role in ribosomal dynamics

  • Super-resolution microscopy to track RPL33A during ribosome assembly

  • Optical tweezers to measure mechanical properties of RPL33A-deficient ribosomes

• Integrative multi-omics approaches:

  • Combined transcriptomics, proteomics, and ribosome profiling

  • Correlation of translation defects with changes in cellular physiology

  • Systems biology modeling of RPL33A's role in ribosome biogenesis

These advanced techniques would provide unprecedented insights into the molecular mechanisms by which RPL33A influences ribosome assembly, pre-rRNA processing, and translation fidelity.

How can RPL33A research contribute to understanding and treating ribosomopathies like Diamond-Blackfan anemia?

RPL33A/RPL35A research has significant implications for understanding and treating ribosomopathies:

• Disease mechanisms:

  • Define the precise molecular pathways disrupted in RPL35A-mutated Diamond-Blackfan anemia

  • Distinguish hematopoietic-specific consequences from general cellular defects

  • Understand why ribosomal protein deficiencies predominantly affect erythroid progenitors

• Biomarker development:

  • Identify pre-rRNA processing signatures specific to RPL35A mutations

  • Develop diagnostic tools based on ribosome assembly defects

  • Create biomarkers to predict treatment response

• Therapeutic strategies:

  • Design targeted approaches to enhance remaining RPL35A function

  • Develop methods to bypass specific pre-rRNA processing defects

  • Identify compounds that rescue translation in RPL35A-deficient cells

• Model systems:

  • Further develop yeast models of DBA for high-throughput screening

  • Create patient-derived induced pluripotent stem cells (iPSCs) to study tissue-specific effects

  • Generate knockin mouse models with specific RPL35A mutations found in DBA patients

The yeast RPL33A system provides a valuable model for studying the fundamental biology of ribosomopathies, with demonstrated utility in understanding the molecular consequences of mutations associated with DBA and potential therapeutic interventions .

What is the current understanding of cross-talk between RPL33A and translation initiation factors?

Recent research has revealed intriguing connections between RPL33A and translation initiation factors:

• Genetic interactions:

  • rpl33a mutations exhibit genetic interactions with eIF1

  • Overexpression of eIF1 suppresses the Sui⁻ phenotype (increased UUG/AUG initiation ratio) of rpl33a mutants

  • These interactions suggest functional cross-talk between the large ribosomal subunit and initiation factor activity

• Mechanistic insights:

  • RPL33A appears to influence the stability of the pre-initiation complex (PIC)

  • Proper 60S/40S subunit ratio is critical for accurate start codon recognition

  • RPL33A may affect the transition from open to closed conformations of the PIC during start codon recognition

• Experimental evidence:

  • rpl33a mutants show constitutive derepression of GCN4 translation (Gcd⁻ phenotype)

  • The reinitiation mechanism governing GCN4 translation is highly sensitive to TC (eIF2-GTP-tRNAi) levels

  • RPL33A deficiency affects scanning and reinitiation processes depending on TC availability

• Research approaches:

  • Genetic suppressor screens to identify additional interactions

  • Structural studies of initiation factor binding in the context of RPL33A mutations

  • Reconstituted translation systems to directly assess RPL33A's influence on initiation factor function